Inventor · disambiguated record
Mark Merchant
Also filed as: MERCHANT MARK · MERCHANT MARK A · MERCHANT MARK ANDREW
8 granted patents·10 pending applications·54 citations·filing 1995–2024
82Inventor score
Top patents by PatentIndex Score
18 records- 0187US12016862B2Methods and compositions comprising a KRasG12C inhibitor and a VEGF inhibitor for treating solid tumorsGENENTECH INC·Filed 2021·Granted Jun 25, 2024·2 cites·19 claims
- 0281US10959993B2Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancerGENENTECH INC·Filed 2016·Granted Mar 30, 2021·2 cites·12 claims
- 0380US5598811ALitter saving waste container systemFiled 1995·Granted Feb 4, 1997·45 cites·3 claims
- 0475US12409178B2Methods and compositions comprising a KRasG12C inhibitor and a VEGF inhibitor for treating solid tumorsGENENTECH INC·Filed 2024·Granted Sep 9, 2025·0 cites·19 claims
- 0575US9150548B2Combinations of AKT inhibitor compounds and vemurafenib, and methods of useHOEFLICH KLAUS·Filed 2012·Granted Oct 6, 2015·4 cites·14 claims
- 0669US12383557B2Treatment of cancer using combination therapies comprising GDC-6036 and GDC-0077GENENTECH INC·Filed 2023·Granted Aug 12, 2025·0 cites·18 claims
- 0767US9532987B2Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseasesGENENTECH INC·Filed 2014·Granted Jan 3, 2017·1 cites·8 claims
- 0861US2009226443A1Combination therapy with c-met and egfr antagonistsGENENTECH INC·Filed 2009·Application pending·0 cites
- 0960US2025312339A1Methods and compositions comprising a shp2 inhibitor and a pd-li binding antagonistGENENTECH INC·Filed 2023·Application pending·0 cites
- 1058US2021169865A1Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancerGENENTECH INC·Filed 2021·Application pending·0 cites
- 1155US2015056207A1Combination therapy with c-met and egfr antagonistsGENENTECH INC·Filed 2014·Application pending·0 cites
- 1253US12171763B2Methods and compositions comprising a KRASG12C inhibitor and a PD-L1 binding antagonist for treating lung cancerGENENTECH INC·Filed 2021·Granted Dec 24, 2024·0 cites·13 claims
- 1352US2015125452A1Combination treatments comprising c-met antagonists and b-raf antagonistsGENENTECH INC·Filed 2014·Application pending·0 cites
- 1451US2022193077A1Methods and compositions comprising a krasg12c inhibitor and a egfr-inhibitor for treating solid tumorsGENENTECH INC·Filed 2021·Application pending·0 cites
- 1548US2021332143A1Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonistGENENTECH INC·Filed 2021·Application pending·0 cites
- 1648US2011262436A1Treatment methodGENENTECH INC·Filed 2009·Application pending·0 cites
- 1748US2013078252A1Combination treatments comprising c-met antagonists and b-raf antagonistsGENENTECH INC·Filed 2012·Application pending·0 cites
- 1847US2016303127A1Combination therapy with c-met and egfr antagonistsGENENTECH INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mark Merchant files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →